PDSB
Price
$1.80
Change
-$0.16 (-8.16%)
Updated
Dec 18, 04:59 PM (EDT)
99 days until earnings call
PRME
Price
$2.65
Change
-$0.27 (-9.28%)
Updated
Dec 18, 04:59 PM (EDT)
78 days until earnings call
Ad is loading...

PDSB vs PRME

Header iconPDSB vs PRME Comparison
Open Charts PDSB vs PRMEBanner chart's image
PDS Biotechnology
Price$1.80
Change-$0.16 (-8.16%)
Volume$1.94K
CapitalizationN/A
Prime Medicine
Price$2.65
Change-$0.27 (-9.28%)
Volume$5.27K
CapitalizationN/A
PDSB vs PRME Comparison Chart
Loading...
PDSB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PDSB vs. PRME commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PDSB is a Hold and PRME is a Hold.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (PDSB: $1.96 vs. PRME: $2.91)
Brand notoriety: PDSB and PRME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PDSB: 79% vs. PRME: 95%
Market capitalization -- PDSB: $73.32M vs. PRME: $381.68M
PDSB [@Biotechnology] is valued at $73.32M. PRME’s [@Biotechnology] market capitalization is $381.68M. The market cap for tickers in the [@Biotechnology] industry ranges from $486.73B to $0. The average market capitalization across the [@Biotechnology] industry is $2.68B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PDSB’s FA Score shows that 0 FA rating(s) are green whilePRME’s FA Score has 0 green FA rating(s).

  • PDSB’s FA Score: 0 green, 5 red.
  • PRME’s FA Score: 0 green, 5 red.
According to our system of comparison, PDSB is a better buy in the long-term than PRME.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PDSB’s TA Score shows that 5 TA indicator(s) are bullish while PRME’s TA Score has 3 bullish TA indicator(s).

  • PDSB’s TA Score: 5 bullish, 3 bearish.
  • PRME’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, PDSB is a better buy in the short-term than PRME.

Price Growth

PDSB (@Biotechnology) experienced а -8.41% price change this week, while PRME (@Biotechnology) price change was -9.63% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.67%. For the same industry, the average monthly price growth was -1.91%, and the average quarterly price growth was -1.42%.

Reported Earning Dates

PDSB is expected to report earnings on Mar 27, 2025.

PRME is expected to report earnings on Mar 06, 2025.

Industries' Descriptions

@Biotechnology (-6.67% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PRME($382M) has a higher market cap than PDSB($73.3M). PDSB YTD gains are higher at: -60.563 vs. PRME (-67.156).
PDSBPRMEPDSB / PRME
Capitalization73.3M382M19%
EBITDAN/AN/A-
Gain YTD-60.563-67.15690%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total Debt24.1MN/A-
FUNDAMENTALS RATINGS
PDSB vs PRME: Fundamental Ratings
PDSB
PRME
OUTLOOK RATING
1..100
6456
VALUATION
overvalued / fair valued / undervalued
1..100
41
Fair valued
71
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
8890
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PDSB's Valuation (41) in the Pharmaceuticals Major industry is in the same range as PRME (71) in the null industry. This means that PDSB’s stock grew similarly to PRME’s over the last 12 months.

PDSB's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as PRME (100) in the null industry. This means that PDSB’s stock grew similarly to PRME’s over the last 12 months.

PDSB's SMR Rating (99) in the Pharmaceuticals Major industry is in the same range as PRME (100) in the null industry. This means that PDSB’s stock grew similarly to PRME’s over the last 12 months.

PDSB's Price Growth Rating (88) in the Pharmaceuticals Major industry is in the same range as PRME (90) in the null industry. This means that PDSB’s stock grew similarly to PRME’s over the last 12 months.

PDSB's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as PRME (100) in the null industry. This means that PDSB’s stock grew similarly to PRME’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PDSBPRME
RSI
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 2 days ago
88%
N/A
Declines
ODDS (%)
Bearish Trend 6 days ago
88%
Bearish Trend 6 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
71%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
PDSB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME31.261.82
+6.18%
GameStop Corp
TSLA479.8616.84
+3.64%
Tesla
AAPL253.482.44
+0.97%
Apple
BTC.X106140.600000110.890625
+0.10%
Bitcoin cryptocurrency
SPY604.29-2.50
-0.41%
SPDR® S&P 500® ETF Trust

PDSB and

Correlation & Price change

A.I.dvisor indicates that over the last year, PDSB has been loosely correlated with RXRX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if PDSB jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PDSB
1D Price
Change %
PDSB100%
+1.29%
RXRX - PDSB
45%
Loosely correlated
-4.30%
BPMC - PDSB
43%
Loosely correlated
+1.14%
PRME - PDSB
42%
Loosely correlated
-3.00%
PGEN - PDSB
42%
Loosely correlated
+2.46%
NTLA - PDSB
41%
Loosely correlated
-1.87%
More

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
-3.00%
CRSP - PRME
64%
Loosely correlated
+0.88%
BEAM - PRME
62%
Loosely correlated
-1.21%
NTLA - PRME
60%
Loosely correlated
-1.87%
RXRX - PRME
56%
Loosely correlated
-4.30%
ABCL - PRME
54%
Loosely correlated
-2.45%
More